Tandem Diabetes Care (TNDM) Capital Expenditures Growth (3y) (2016 - 2026)
Tandem Diabetes Care (TNDM) Capital Expenditures Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.13 Bn | 175.83 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 108.98 Bn | 99.76 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 68.45 Bn | 67.00 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 48.01 Bn | 44.34 Bn | 1.29 Bn | 1.81% |
| 6 | GE HealthCare Technologies | 28.29 Bn | 26.01 Bn | 1.98 Bn | 7.57% |
| 7 | Dexcom | 28.25 Bn | 27.13 Bn | 750.30 Mn | 0.84% |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.32 Bn | 2.07 Bn | 2.15% |
| 10 | Tandem Diabetes Care | 1.14 Bn | 567.19 Mn | 136.79 Mn | -10.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.79% |
| Dec 31, 2025 | 200.24% |
| Sep 30, 2025 | 251.21% |
| Jun 30, 2025 | -68.82% |
| Mar 31, 2025 | 72.07% |
| Dec 31, 2024 | -177.55% |
| Sep 30, 2024 | 916.33% |
| Jun 30, 2024 | 278.65% |
| Mar 31, 2024 | 473.94% |
| Dec 31, 2023 | -24.97% |
| Sep 30, 2023 | -38.75% |
| Jun 30, 2023 | 48.49% |
| Mar 31, 2023 | 9.27% |
| Dec 31, 2022 | -66.80% |
| Sep 30, 2022 | -26.49% |
| Jun 30, 2022 | 33.16% |
| Mar 31, 2022 | 64.81% |
| Dec 31, 2021 | 34.34% |
| Sep 30, 2021 | -26.10% |
| Jun 30, 2021 | -37.19% |